EXACT SCIENCES CORP

EXAS

EXACT SCIENCES CORP

EXAS

Insider Sentiment (TTM):

Last Purchase:2024-11-13Last Sale:2025-11-19Shares Purchased (TTM):0Shares Sold (TTM):25,858

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:43,466Shares Outstanding:188,688,000Institutional Ownership Pct.:0.02%

Earnings Market Reaction:

Filing Date:2026-02-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	956	789	657	347	601	589	530	347	605	595	604	421
Marketable Securities Current	9	214	201	439	437	432	417	305	172	140	171	277
Accounts Receivable Net Current	299	306	353	280	249	265	264	241	204	199	178	183
Inventory Net	166	165	171	177	162	137	127	129	127	133	131	124
Prepaid Expense And Other Assets Current	126	117	125	128	122	110	114	99	86	82	89	85
Assets Current	1,556	1,591	1,508	1,370	1,571	1,533	1,452	1,120	1,194	1,148	1,174	1,091
Assets Noncurrent
Property Plant And Equipment Net	709	704	705	698	694	690	703	702	698	692	687	685
Operating Lease Right Of Use Asset	122	121	126	127	117	122	140	142	144	150	149	157
Goodwill	2,368	2,368	2,368	2,367	2,367	2,367	2,367	2,367	2,367	2,367	2,346	2,346
Intangible Assets Net Excluding Goodwill	920	941	965	989	1,010	1,864	1,843	1,867	1,890	1,913	1,911	1,933
Other Assets Noncurrent	186	175	125	160	170	171	167	178	177	151	90	92
Assets	5,861	5,900	5,797	5,711	5,928	6,749	6,673	6,376	6,471	6,421	6,356	6,304
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	176	129	157	142	90	98	53	60	79	74	75	87
Accrued Liabilities Current	416	409	317	295	328	314	303	265	342	310	300	242
Operating Lease Liability Current	34	32	31	30	27	27	27	27	29	30	30	30
Other Liabilities Current	15	14	16	35	38	36	37	33	15	13	34	9
Convertible Notes Payable Current	0	0	0	0	249	249	249	249	0	-	-	-
Liabilities Current	641	584	522	502	732	724	669	685	515	477	488	367
Liabilities Noncurrent
Convertible Long Term Notes Payable	2,327	2,326	2,324	2,323	2,321	2,319	2,318	2,067	2,314	2,313	2,312	2,310
Long Term Loans Payable	-	-	-	-	-	-	-	-	0	0	0	50
Other Liabilities Noncurrent	329	325	316	320	316	332	327	329	336	342	331	344
Operating Lease Liability Noncurrent	162	164	166	169	157	163	168	162	161	168	169	175
Liabilities	3,460	3,399	3,328	3,314	3,526	3,538	3,481	3,244	3,326	3,300	3,299	3,247
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	2	2	2	2	2	2	2	2	2	2	2	2
Additional Paid In Capital Common Stock	7,103	7,116	7,065	6,993	6,899	6,837	6,787	6,711	6,611	6,540	6,476	6,397
Accumulated Other Comprehensive Income Loss Net Of…	2	3	3	1	-1	5	-1	-0	1	-2	-1	-2
Retained Earnings Accumulated Deficit	-4,706	-4,620	-4,600	-4,599	-4,498	-3,633	-3,595	-3,579	-3,469	-3,419	-3,420	-3,339
Stockholders Equity	2,401	2,501	2,469	2,397	2,402	3,211	3,192	3,133	3,145	3,121	3,057	3,058
Liabilities And Stockholders Equity	5,861	5,900	5,797	5,711	5,928	6,749	6,673	6,376	6,471	6,421	6,356	6,304
Loans Payable Current	-	-	-	-	0	0	0	50	50	50	50	-
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	400
Common Stock Shares Issued	191	189	189	189	186	185	185	184	181	181	181	180
Shares Outstanding	191	189	189	189	186	185	185	184	181	181	181	180

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	20.76%	12.43%	7.00%	1.09%	14.20%	37.80%	51.22%	51.64%	52.67%	0.25%	-	-
2024	-23.59%	-28.97%	-23.84%	30.69%	53.44%	57.46%	-13.19%	-19.52%	-21.72%	-10.86%	-11.95%	2.28%
2023	18.08%	32.25%	39.49%	-16.57%	-30.68%	-33.38%	3.89%	15.73%	3.67%	-8.82%	12.72%	-15.45%
2022	-	-	-	-	-	-	-	-	-	3.56%	9.03%	29.27%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Liquidity Ratios
Current Ratio	2.43	2.72	2.89	2.73	2.15	2.12	2.17	1.64	2.32	2.41	2.41	2.97
Quick Ratio	1.97	2.24	2.32	2.12	1.76	1.78	1.81	1.30	1.91	1.96	1.95	2.40
Working Capital	914.70M	1.01B	985.93M	867.88M	839.24M	809.46M	783.85M	435.16M	679.67M	671.67M	685.87M	724.03M
Leverage & Debt
Debt to Equity	1.44	1.36	1.35	1.38	1.47	1.10	1.09	1.04	1.06	1.06	1.08	1.06
Interest Coverage TTM	-5.24	-25.53	-26.00	-35.46	-38.50	-13.60	-12.18	-10.35	-10.86	-13.44	-23.95	-35.63
Debt Ratio	0.59	0.58	0.57	0.58	0.59	0.52	0.52	0.51	0.51	0.51	0.52	0.51
Efficiency & Turnover
Asset Turnover TTM	0.14	0.13	0.13	0.13	0.11	0.11	0.11	0.10	0.10	0.10	0.10	0.10
Days Sales Outstanding TTM	117.48	122.46	137.28	122.08	116.56	119.55	114.38	116.63	105.05	112.87	106.79	111.11
Receivables Turnover TTM	3.11	2.98	2.66	2.99	3.13	3.05	3.19	3.13	3.47	3.23	3.42	3.29
Per Share Metrics
Diluted EPS TTM	-1.10	-5.21	-5.32	-5.46	-5.59	-1.16	-0.95	-1.32	-1.13	-1.53	-2.40	-2.89
Free Cash Flow Per Share TTM	1.89	1.31	0.90	1.04	0.40	0.53	-0.08	-0.11	0.18	-0.13	-0.60	-1.67
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	265.98%	245.12%	242.89%	253.62%	270.75%	-	-	-	-	-	-	-
Operating Profit Margin TTM	-24.25%	-117.55%	-123.58%	-133.44%	-147.98%	-33.89%	-27.49%	-36.87%	-34.22%	-42.34%	-65.91%	-77.25%
Net Profit Margin TTM	-24.44%	-115.97%	-122.52%	-131.10%	-145.18%	-30.20%	-24.81%	-36.21%	-32.49%	-44.90%	-69.23%	-80.87%
Growth Metrics
Net Revenue Growth (1Y)	20.05%	20.05%	16.30%	17.26%	12.78%	12.78%	13.15%	3.83%	20.12%	20.12%	14.79%	18.13%
Net Income Growth (1Y)	-79.79%	360.94%	474.39%	324.54%	403.97%	-24.13%	-59.46%	-53.51%	-67.26%	-60.62%	-41.23%	-30.68%
EPS Growth (1Y)	-80.27%	350.06%	460.43%	314.39%	392.88%	-25.84%	-60.36%	-54.47%	-67.95%	-61.41%	-42.48%	-32.29%
Calculated Values
Free Cash Flow TTM	356.78M	247.08M	169.62M	194.14M	74.55M	98.43M	-14.96M	-20.46M	31.93M	-23.54M	-108.27M	-298.22M
Net Debt	1.37B	1.54B	1.67B	1.98B	1.96B	1.97B	2.03B	2.02B	1.75B	1.77B	1.76B	1.89B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-11-19Sale

Owner: Orville, Jacob A

Title: EVP, GM, Screening

Shares: 5,000

Price/Share: $75.00

Value: $375,000.00

Shares Owned: 23,237

Relationship: Officer

Ownership: Direct

2025-11-19Sale

Owner: Herriott, James

Title: SVP, General Counsel & Sec

Shares: 1,000

Price/Share: $70.00

Value: $70,000.00

Shares Owned: 11,585

Relationship: Officer

Ownership: Direct

2025-11-04Sale

Owner: Baranick, Brian

Title: EVP, GM, Precision Oncology

Shares: 2,858

Price/Share: $70.08

Value: $200,288.64

Shares Owned: 22,368

Relationship: Officer

Ownership: Direct

2025-11-04Sale

Owner: Herriott, James

Title: SVP, General Counsel & Sec

Shares: 1,500

Price/Share: $70.08

Value: $105,120.00

Shares Owned: 12,585

Relationship: Officer

Ownership: Direct

2025-10-24Sale

Owner: Zanotti, Katherine S

Title: -

Shares: 12,000

Price/Share: $65.00

Value: $780,000.00

Shares Owned: 60,759

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-11-19	Orville, Jacob A	Officer	EVP, GM, Screening	Direct	Sale	5,000	75.00	$375,000.00	23,237	4
2025-11-19	Herriott, James	Officer	SVP, General Counsel & Sec	Direct	Sale	1,000	70.00	$70,000.00	11,585	4
2025-11-04	Baranick, Brian	Officer	EVP, GM, Precision Oncology	Direct	Sale	2,858	70.08	$200,288.64	22,368	4
2025-11-04	Herriott, James	Officer	SVP, General Counsel & Sec	Direct	Sale	1,500	70.08	$105,120.00	12,585	4
2025-10-24	Zanotti, Katherine S	Director	-	Direct	Sale	12,000	65.00	$780,000.00	60,759	4
2025-10-09	Herriott, James	Officer	SVP, General Counsel & Sec	Direct	Sale	1,500	60.00	$90,000.00	14,085	4
2025-10-09	Doyle, James Edward	Director	-	Direct	Sale	2,000	60.00	$120,000.00	57,962	4
2025-08-13	Doyle, James Edward	Director	-	Direct	Sale	1,485	42.02	$62,399.70	59,962	4
2025-06-13	Zanotti, Katherine S	Director	-	Direct	Sale	3,207	53.20	$170,612.40	72,759	4
2024-11-13	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Purchase	19,500	51.35	$1,001,325.00	1,074,191	4
2024-10-08	Baranick, Brian	Officer	EVP, GM, Precision Oncology	Direct	Sale	929	70.00	$65,030.00	12,758	4
2024-09-18	Baranick, Brian	Officer	EVP, GM, Precision Oncology	Direct	Sale	929	70.00	$65,030.00	13,687	4
2024-05-01	Cunningham, Everett	Officer	Chief Commercial Officer	Direct	Sale	136	60.15	$8,180.40	47,042	4
2024-05-01	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	136	60.15	$8,180.40	11,795	4
2024-05-01	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	1,155	60.15	$69,473.25	1,156,191	4
2024-05-01	Baranick, Brian	Officer	EVP, GM., Precision Oncology	Direct	Sale	110	60.15	$6,616.50	13,279	4
2024-05-01	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	102	60.15	$6,135.30	14,440	4
2024-05-01	Herriott, James	Officer	SVP, General Counsel & Sec	Direct	Sale	30	60.15	$1,804.50	9,866	4
2024-05-01	Coward, D Scott	Director	-	Direct	Sale	67	60.15	$4,030.05	44,644	4
2024-05-01	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	102	60.15	$6,135.30	72,611	4
2024-04-02	Baranick, Brian	Officer	EVP, GM., Precision Oncology	Direct	Sale	924	79.43	$73,393.32	13,171	4
2024-04-01	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	2,000	70.00	$140,000.00	71,787	4
2024-03-28	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	2,000	70.00	$140,000.00	73,787	4
2024-03-01	Doyle, James Edward	Director	-	Direct	Sale	2,000	57.50	$115,000.00	50,110	4
2024-03-01	Baranick, Brian	Officer	Gen. Mgr., Precision Oncology	Direct	Sale	2,323	59.32	$137,800.36	14,095	4
2024-03-01	Herriott, James	Officer	General Counsel	Direct	Sale	862	59.32	$51,133.84	9,125	4
2024-03-01	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	8,271	59.32	$490,635.72	1,299,496	4
2024-03-01	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	2,412	59.32	$143,079.84	10,933	4
2024-03-01	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	2,154	59.32	$127,775.28	14,324	4
2024-03-01	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,724	59.32	$102,267.68	75,787	4
2024-03-01	Cunningham, Everett	Officer	Chief Commercial Officer	Direct	Sale	2,412	59.32	$143,079.84	46,179	4
2024-03-01	Levangie, Daniel J	Director	-	Direct	Sale	5,000	57.50	$287,500.00	22,975	4
2024-02-27	Cunningham, Everett	Officer	Chief Commercial Officer	Direct	Sale	3,648	56.89	$207,534.72	43,300	4
2024-02-27	Baranick, Brian	Officer	Gen. Mgr., Precision Oncology	Direct	Sale	2,027	56.89	$115,316.03	11,694	4
2024-02-27	Herriott, James	Officer	General Counsel	Direct	Sale	784	56.89	$44,601.76	8,097	4
2024-02-27	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	2,710	56.89	$154,171.90	8,054	4
2024-02-27	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	1,879	56.89	$106,896.31	11,754	4
2024-02-27	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	6,263	56.89	$356,302.07	1,289,624	4
2024-02-27	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,880	56.89	$106,953.20	73,732	4
2024-02-23	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,021	59.72	$60,974.12	71,658	4
2024-02-22	Baranick, Brian	Officer	Gen. Mgr., Precision Oncology	Direct	Sale	1,093	59.78	$65,339.54	9,767	4
2024-02-22	Cunningham, Everett	Officer	Chief Commercial Officer	Direct	Sale	1,350	59.78	$80,703.00	39,270	4
2024-02-22	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	1,013	59.78	$60,557.14	9,679	4
2024-02-22	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	1,351	59.78	$80,762.78	5,063	4
2024-02-22	Coward, D Scott	Director	-	Direct	Sale	663	59.78	$39,634.14	44,493	4
2024-02-22	Herriott, James	Officer	General Counsel	Direct	Sale	291	59.78	$17,395.98	7,233	4
2024-02-22	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	11,565	59.78	$691,355.70	1,241,429	4
2024-02-22	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,013	59.78	$60,557.14	72,679	4
2024-02-21	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	4,975	61.50	$305,962.50	1,229,756	4
2024-02-21	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	1,493	61.50	$91,819.50	3,703	4
2024-02-21	Coward, D Scott	Director	-	Direct	Sale	706	61.50	$43,419.00	43,122	4
2024-02-21	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,079	61.50	$66,358.50	71,658	4
2024-02-21	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	1,078	61.50	$66,297.00	8,658	4
2024-02-21	Baranick, Brian	Officer	Gen. Mgr., Precision Oncology	Direct	Sale	895	61.50	$55,042.50	8,826	4
2024-02-21	Herriott, James	Officer	General Counsel	Direct	Sale	415	61.50	$25,522.50	6,943	4
2024-02-15	Herriott, James	Officer	General Counsel	Direct	Sale	421	61.43	$25,862.03	6,494	4
2024-02-15	Coward, D Scott	Director	-	Direct	Sale	1,376	61.43	$84,527.68	41,580	4
2024-02-15	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	14,791	61.43	$908,611.13	1,224,357	4
2024-02-15	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	1,888	61.43	$115,979.84	2,084	4
2024-02-15	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	965	61.43	$59,279.95	70,489	4
2024-02-15	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	966	61.43	$59,341.38	7,488	4
2024-01-02	Baranick, Brian	Officer	Gen. Mgr., Precision Oncology	Direct	Sale	879	73.50	$64,606.50	7,992	4
2024-01-02	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	2,000	73.50	$147,000.00	69,423	4
2023-12-14	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	2,000	70.00	$140,000.00	71,423	4
2023-10-12	Cunningham, Everett	Officer	Chief Commercial Officer	Direct	Sale	13,007	66.49	$864,835.43	37,909	4
2023-09-01	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	4,500	84.36	$379,620.00	75,814	4
2023-08-21	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	30,210	82.92	$2,505,013.20	0	4
2023-08-07	Baranick, Brian	Officer	Gen. Mgr., Precision Oncology	Direct	Sale	1,350	85.04	$114,804.00	8,871	4
2023-07-27	Doyle, James Edward	Director	-	Direct	Sale	2,000	97.42	$194,840.00	52,110	4
2023-07-19	Herriott, James	Officer	General Counsel	Direct	Sale	1,300	100.00	$130,000.00	5,964	4
2023-06-09	Zanotti, Katherine S	Director	-	Direct	Sale	3,027	90.51	$273,973.77	64,629	4
2023-06-09	Doyle, James Edward	Director	-	Direct	Sale	1,402	90.51	$126,895.02	54,110	4
2023-06-08	Herriott, James	Officer	General Counsel	Direct	Sale	1,300	90.00	$117,000.00	7,264	4
2023-05-26	Doyle, James Edward	Director	-	Direct	Sale	2,000	80.62	$161,240.00	51,913	4
2023-05-10	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	5,000	80.00	$400,000.00	6,423	4
2023-05-10	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	6,087	80.00	$486,960.00	80,314	4
2023-05-10	Herriott, James	Officer	General Counsel	Direct	Sale	1,300	79.85	$103,805.00	8,564	4
2023-05-01	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,000	63.78	$63,780.00	86,401	4
2023-04-03	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,000	67.19	$67,190.00	86,692	4
2023-03-03	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	5,000	65.00	$325,000.00	11,423	4
2023-03-01	Cunningham, Everett	Officer	Chief Commercial Officer	Direct	Sale	3,628	62.01	$224,972.28	22,703	4
2023-03-01	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,000	62.00	$62,000.00	87,692	4
2023-02-28	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	6,832	60.55	$413,677.60	16,423	4
2023-02-28	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	4,233	61.12	$258,720.96	29,241	4
2023-02-28	Coward, D Scott	Director	-	Direct	Sale	4,153	61.12	$253,831.36	32,775	4
2023-02-28	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	10,416	61.12	$636,625.92	1,207,306	4
2023-02-28	Herriott, James	Officer	General Counsel	Direct	Sale	2,225	60.55	$134,723.75	9,224	4
2023-02-28	Baranick, Brian	Officer	Gen. Mgr., Precision Oncology	Direct	Sale	1,932	61.12	$118,083.84	7,509	4
2023-02-28	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	2,924	61.12	$178,714.88	88,692	4
2023-02-22	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	1,430	62.72	$89,689.60	24,337	4
2023-02-22	Herriott, James	Officer	General Counsel	Direct	Sale	398	62.72	$24,962.56	9,562	4
2023-02-22	Baranick, Brian	Officer	Gen. Mgr., Precision Oncology	Direct	Sale	838	62.72	$52,559.36	5,487	4
2023-02-22	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	2,710	62.72	$169,971.20	19,301	4
2023-02-22	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	4,764	62.72	$298,798.08	1,195,230	4
2023-02-22	Coward, D Scott	Director	-	Direct	Sale	1,007	62.72	$63,159.04	27,734	4
2023-02-22	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,033	62.72	$64,789.76	85,305	4
2023-02-16	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,076	63.91	$68,767.16	84,090	4
2023-02-15	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	954	65.59	$62,572.86	85,166	4
2023-02-15	Orville, Jacob A	Officer	General Manager, Screening	Direct	Sale	954	69.59	$66,388.86	16,114	4
2023-02-15	Coward, D Scott	Director	-	Direct	Sale	1,821	65.59	$119,439.39	26,493	4
2023-02-15	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	14,617	65.59	$958,729.03	1,189,620	4
2023-02-15	Herriott, James	Officer	General Counsel	Direct	Sale	400	65.59	$26,236.00	9,095	4
2023-02-15	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	1,866	65.59	$122,390.94	22,655	4
2023-02-13	Conroy, Kevin T	Director,Officer	President and CEO	Direct	Sale	4,527	64.55	$292,217.85	1,173,105	4
2023-02-13	Elliott, Jeffrey Thomas	Officer	Chief Financial Officer	Direct	Sale	1,158	64.55	$74,748.90	20,549	4
2023-02-01	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,000	67.93	$67,930.00	84,090	4
2023-01-09	Condella, Sarah	Officer	EVP, Human Resources	Direct	Sale	1,000	60.00	$60,000.00	85,090	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

0.02%

Inst. Shares: 43,466

Shares Outstanding: 188,688,000

2025-12-31

82.56%

Inst. Shares: 155,773,314

Shares Outstanding: 188,688,000

2025-09-30

91.60%

Inst. Shares: 173,368,712

Shares Outstanding: 189,262,000

2025-06-30

90.96%

Inst. Shares: 171,817,823

Shares Outstanding: 188,902,000

2025-03-31

90.85%

Inst. Shares: 169,713,743

Shares Outstanding: 186,813,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	43,466	188,688,000	0.02%
2025-12-31	155,773,314	188,688,000	82.56%
2025-09-30	173,368,712	189,262,000	91.60%
2025-06-30	171,817,823	188,902,000	90.96%
2025-03-31	169,713,743	186,813,000	90.85%
2024-12-31	169,757,615	184,197,000	92.16%
2024-09-30	171,922,762	184,795,000	93.03%
2024-06-30	171,251,615	184,313,000	92.91%
2024-03-31	152,080,155	182,350,000	83.40%
2023-12-31	151,508,754	180,144,000	84.10%
2023-09-30	151,909,834	180,649,000	84.09%
2023-06-30	151,218,385	180,204,000	83.92%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

EXACT SCIENCES CORP (EXAS) — SEC Financial Statements & Analysis

EXACT SCIENCES CORP (EXAS) is a services-medical laboratories company. EXACT SCIENCES CORP trades on Nasdaq as: EXAS. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), EXACT SCIENCES CORP reported a 20.05% year-over-year revenue growth, a Gross Profit Margin of 265.98% (TTM), a Debt-to-Equity ratio of 1.44x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 20.05%
Gross Profit Margin TTM: 265.98%
Debt To Equity: 1.44x

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is EXACT SCIENCES CORP in?

EXACT SCIENCES CORP (EXAS) operates in the Services-Medical Laboratories industry.

What exchange does EXAS trade on?

EXACT SCIENCES CORP (EXAS) trades on the Nasdaq.